Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 18.

Journal Article

Ackermann, S., Cartolano, M., Hero, B., Roderwieser, A., Bartenhagen, C., Rosswog, C., Hertwig, F., Simon, T., Eggert, A., Speleman, F., Buettner, R., O'Sullivan, R., Thomas, R., Berthold, F., Vandesompele, J., Schramm, A., Westermann, F., Schulte, J., Peifer, M. and Fischer, M. (2018). A Mechanistic Classification of Clinical Phenotypes in Neuroblastoma. Pediatr. Blood Cancer, 65. S. S87 - 2. HOBOKEN: WILEY. ISSN 1545-5017

Ackermann, S., Cartolano, M., Hero, B., Roderwieser, A., Bartenhagen, C., Rosswog, C., Hertwig, F., Simon, T., Eggert, A., Speleman, F., Buettner, R., O'sullivan, R., Thomas, R., Berthold, F., Vandesompele, J., Schramm, A., Westermann, F., Schulte, J., Peifer, M. and Fischer, M. (2018). A Mechanistic Classification of Clinical Phenotypes in Neuroblastoma. Pediatr. Blood Cancer, 65. S. S234 - 1. HOBOKEN: WILEY. ISSN 1545-5017

Dietlein, F., Kalb, B., Jokic, M., Torgovnick, A., Schmitt, A., Buettner, R., Thomas, R. and Reinhardt, H. C. (2015). Combined Chk1-and MK2-inhibition displays robust synergy in KRAS-mutant cancer. Oncol. Res. Treat., 38. S. 169 - 170. BASEL: KARGER. ISSN 2296-5262

Fischer, R. N., Abdulla, D., Michels, S., Nogova, L., Brandes, V, Scheffler, M., Schaeffer, S., Scheel, A., Thurat, M., Vehreschild, M., Thomas, R., von Bergwelt-Baildon, M., Buettner, R. and Wolf, J. (2016). Bioluma: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer - A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition. Oncol. Res. Treat., 39. S. 92 - 94. BASEL: KARGER. ISSN 2296-5262

Fischer, R. N., George, J., Schaefer, S., Scheel, A., Schloesser, H., Vehreschild, M., von Bergwelt-Baildon, M., Nogova, L., Abdulla, D. S. Y., Michels, S., Riedel, R., Scheffler, M., Brossart, P., Engel-Riedel, W., Griesinger, F., Grohe, C., Kambartel, K., Kern, J., Kopp, H-G, Neukirchen, J., Overbeck, T. R., Panse, J., Sebastian, M., Serke, M., Wiewrodt, R., Buettner, R., Thomas, R. and Wolf, J. (2018). BIOLUMA: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer. Oncol. Res. Treat., 41. S. 270 - 272. BASEL: KARGER. ISSN 2296-5262

Fischer, R. N., George, J., Scheel, A., Schloesser, H., Brossart, P., Engel-Riedel, W., Griesinger, F., Grohe, C., Kern, J. K., Panse, J., Sebastian, M., Serke, M., Wiewrodt, R., Michels, S., Nogova, L., Riedel, R., Weber, J-P., Buettner, R., Thomas, R. and Wolf, J. (2022). BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response - results from the NSCLC cohort. Ann. Oncol., 33 (7). S. S1025 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Heuckmann, J., Leenders, F. and Thomas, R. (2014). Development of the Cancer Genome Scanner (CAGE), a single tube cancer assay for deep genomic analysis of point mutations, insertions and deletions, copy number alterations and gene fusions. Oncol. Res. Treat., 37. S. 96 - 97. BASEL: KARGER. ISSN 2296-5262

Koenig, K., Peifer, M., Bos, M., Nogova, L., Merkelbach-Bruse, S., Stamm, K., Henkel, T., Thomas, R., Wolf, J., Buettner, R. and Heukamp, L. (2014). High throughput parallel amplicon sequencing of common driver mutations from FFPE lung cancer samples in molecular pathological routine diagnostics for a regional health care provider network. Oncol. Res. Treat., 37. S. 31 - 33. BASEL: KARGER. ISSN 2296-5262

Kron, A., Alidousty, C., Scheffler, M., Merkelbach-Bruse, S., Seidel, D., Riedel, R., Ihle, M. A., Michels, S., Nogova, L., Fassunke, J., Heydt, C., Kron, F., Ueckeroth, F., Serke, M., Krueger, S. ORCID: 0000-0002-1658-5993, Grohe, C., Koschel, D., Benedikter, J., Kaminsky, B., Schaaf, B., Braess, J., Sebastian, M., Kambartel, K. -O., Thomas, R., Zander, T., Schultheis, A. M., Buettner, R. and Wolf, J. (2018). Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann. Oncol., 29 (10). S. 2068 - 2076. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Marquez, Ma Garcia, Thelen, M., Bauer, E., Wennhold, K., Lehmann, J., Keller, D., Maas, L., Nicolik, M., George, J., Zander, T., Schroeder, W., Mueller, P., Bruns, C., Thomas, R., Gathof, B., Quaas, A., Hillmer, A. M., Peifer, M., von Bergwelt-Baildon, M. and Schloesser, H. A. (2022). HEREDITARY HOMOZYGOSITY AND ALLELIC IMBALANCE OF HLA AS COMMON IMMUNE ESCAPE MECHANISMS IN ESOPHAGEAL ADENOCARCINOMA. J. Immunother. Cancer, 10. S. A38 - 1. LONDON: BMJ PUBLISHING GROUP. ISSN 2051-1426

Michels, S., Gardizi, M., Schultheis, A., Scheffler, M., Karachaliou, N., Teixido, C., Heukamp, L., Merkelbach-Bruse, S., Thurat, M., Nogova, L., Bos, M., Mattonet, C., Grohe, C., Sebastian, M., Thomas, M., Reck, M., Stahel, R., Pirker, R., Zoechbauer-Mueller, S., Groen, H., Dingemanns, A. -M, Smit, E., Thomas, R., Buettner, R., Massuti, B., Rosell, R. and Wolf, J. (2014). EUCROSS: A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations. Oncol. Res. Treat., 37. S. 65 - 66. BASEL: KARGER. ISSN 2296-5262

Nogova, L., Gardizi, M., Bos, M., Scheffler, M., Papachristou, I., Woempner, C., Heukamp, L., Schildhaus, H. -U., Fuhr, U., Sos, M., Eberhardt, W., Wiesweg, M., Schmid, K. W., Schuler, M., Thomas, R., Buettner, R. and Wolf, J. (2014). TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262

Nogova, L., Malchers, F., Zadoyan, G., Hillmer, A., Merkelbach-Bruse, S., Riedel, R., Michels, S., Masouleh, Kharabi B., De Porre, P., Santiago-Walker, A., Scheffler, M., Fischer, R. N., Abdulla, D. S. Y., Thomas, R., Buettner, R. and Wolf, J. (2018). FIND trial: a phase II study to evaluate the efficacy of the FGFR-inhibitor erdafitinib in FGFR-mutated and - translocated squamous NSCLC (trial in progress). Oncol. Res. Treat., 41. S. 294 - 295. BASEL: KARGER. ISSN 2296-5262

Rosswog, C., Bartenhagen, C., Ackermann, S., Perner, S., Vogel, W., Altmueller, J., Nuernberg, P., Hertwig, F., Gohring, G., Lilienweiss, E., Stuetz, A., Korbel, J., Thomas, R., Peifer, M. and Fischer, M. (2020). Circular Recombination Drives Massive Oncogene Amplification and Over-Expression in Human Cancer. Pediatr. Blood Cancer, 67. S. S302 - 1. HOBOKEN: WILEY. ISSN 1545-5017

Rosswog, C., Bartenhagen, C., Engesser, A., Kahlert, Y., Hertwig, F., Roderwieser, A., Hero, B., Peifer, M., Thomas, R. and Fischer, M. (2018). Reconstructing the Evolution of Complex Genomic Amplification Patterns at Chromosome 12q in Neuroblastoma. Pediatr. Blood Cancer, 65. S. S277 - 2. HOBOKEN: WILEY. ISSN 1545-5017

Thelen, L., Chen, S., Riabinska, A., Daheim, M., Jokic, M., Thomas, R. and Reinhardt, C. (2014). Therapeutic targeting of a robust non-oncogene addiction to PRKDC in DNA repair-defective tumors. Oncol. Res. Treat., 37. S. 97 - 98. BASEL: KARGER. ISSN 2296-5262

Tischler, V., Ihle, M. A., Stenzinger, A., Weichert, W., Jochum, W., Buettner, R., Wolf, J., Peifer, M. and Thomas, R. (2018). Clonal and subclonal occurrence of oncogenic mutations in lung adenocarcinoma. J. Thorac. Oncol., 13 (4). S. S12 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Weber, J. -P., Fischer, R. N., George, J., Scheel, A., Westphal, T., Koleczko, S., Nogova, L., Riedel, R., Michels, S., Scheffler, M., Abdullah, D. S. Y., Sueptitz, J., Keser, E., Merkelbach-Bruse, S., Pinto, A., Buettner, R., Thomas, R. and Wolf, J. (2020). Small Cell Lung Cancer - Filling the gap between science and patients. Oncol. Res. Treat., 43 (SUPPL 4). S. 154 - 155. BASEL: KARGER. ISSN 2296-5262

This list was generated on Thu Mar 28 16:57:12 2024 CET.